Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic Leukemia (CLL) who achieve partial response: Comprehensive analysis of two phase III Studies of the German CLL Study Group

Journal of Clinical Oncology

Volumn 34, Issue 31, 2016, Pages 3758-3765

  Kovacs, Gabor ^a   Robrecht, Sandra ^a   Fink, Anna Maria ^a   Bahlo, Jasmin ^a   Cramer, Paula ^a   Von Tresckow, Julia ^a   Maurer, Christian ^a   Langerbeins, Petra ^a   Fingerle Rowson, Günter ^f   Ritgen, Matthias ^b   Kneba, Michael ^g   Döhner, Hartmut ^c   Stilgenbauer, Stephan ^c   Klapper, Wolfram ^d   Wendtner, Clemens Martin ^e   Fischer, Kirsten ^a   Hallek, Michael ^a,b   Eichhorst, Barbara ^a   Böttcher, Sebastian ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e Klinikum Schwabing   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 17; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL OUTCOME; FEMALE; HUMAN; LEUKEMIA REMISSION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLEEN SIZE; SPLENOMEGALY; TREATMENT RESPONSE; ADULT; DISEASE FREE SURVIVAL; GERMANY; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; REMISSION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84994048523     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.1305     Document Type: Article

References (32)

1. Tam CS, O'Brien S, Wierda W, et al: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008
2. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophos-phamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
3. Woyach JA, Ruppert AS, Heerema NA, et al: Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712. J Clin Oncol 29:1349-1355, 2011
4. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014
5. Hillmen P, Robak T, Janssens A, et al: Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial. Lancet 385:1873-1883, 2015
6. Eichhorst B, Fink A.-M., Busch R., et al: Frontline chemoimmunotherapy with bendamustine and rituximab is inferior to fludarabine, cyclophosphamide and rituximab in physically fit patients with advanced chronic lymphocytic leukaemia: An international randomized phase III study (CLL10 study of the GCLLSG). Lancet Oncol 17:928-942, 2016
7. Fischer K, Bahlo J, Fink AM, et al: Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 127:208-215, 2016
8. Böttcher S, Hallek M, Ritgen M, et al: The role of minimal residual disease measurements in the therapy for CLL: Is it ready for prime time? Hematol Oncol Clin North Am 27:267-288, 2013
9. Byrd JC, Brown JR, O'Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014
10. Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007, 2014
11. Roberts AW, Davids MS, Pagel JM, et al: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311-322, 2016
12. Stilgenbauer S EB, Schetelig J, Coutre S, et al: Venetoclax in relapsed/refractory chronic lymphocytic leukemia with 17p deletion. Lancet Oncol 17: 768-778, 2016
13. Hallek M: Signaling the end of chronic lymphocytic leukemia: New frontline treatment strategies. Hematology (Am Soc Hematol Educ Program) 2013:138-150, 2013
14. Strati P, Keating MJ, O'Brien SM, et al: Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123:3727-3732, 2014
15. Wierda WG, O'Brien S, Wang X, et al: Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27:1637-1643, 2009
16. Pettitt AR, Jackson R, Carruthers S, et al: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the national cancer research institute CLL206 trial. J Clin Oncol 30: 1647-1655, 2012
17. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007
18. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as firstline therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
19. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
20. Rawstron AC, Kennedy B, Evans PA, et al: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29-35, 2001
21. Böttcher S, Ritgen M, Fischer K, et al: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30:980-988, 2012
22. Moreno C, Villamor N, Colomer D, et al: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107:4563-4569, 2006
23. Bouvet E, Borel C, Obéric L, et al: Impact of dose intensity on outcome of fludarabine, cyclo-phosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Haematologica 98:65-70, 2013
24. Santacruz R, Villamor N, Aymerich M, et al: The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica 99:873-880, 2014
25. European Medicines Agency: Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/12/WC500179047.pdf
26. Fink AM, Böttcher S, Ritgen M, et al: Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophospha-mide and rituximab. Leukemia 27:1949-1952, 2013
27. Rawstron AC, Villamor N, Ritgen M, et al: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956-964, 2007
28. Böttcher S, Stilgenbauer S, Busch R, et al: Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: A comparative analysis. Leukemia 23:2007-2017, 2009
29. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996
30. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
31. Chow KU, Luxembourg B, Seifried E, et al: Spleen size is significantly influenced by body height and sex: Establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals. Radiology 279:306-313, 2016
32. Herishanu Y, Pérez-Galán P, Liu D, et al: The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563-574, 2011